Drug interactions
Trastuzumab + Ublituximab
Severity: Minor
Trastuzumab and Ublituximab: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Ublituximab depletes B cells and can cause infections, while trastuzumab is generally not substantially immunosuppressive. Additive infection risk is therefore largely theoretical, though patients receiving cancer therapy may be more vulnerable.
What this interaction means in plain words
Trastuzumab and Ublituximab have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Trastuzumab belongs to Oncology; Ublituximab belongs to Miscellaneous.
Why it happens
Ublituximab causes B-cell depletion; trastuzumab has little direct immunosuppressive effect, so additive risk is theoretical.
What to do
Monitor for signs of infection and screen for hepatitis B before ublituximab. Delay live vaccines and review neutropenia risk if combined with chemotherapy.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Trastuzumab and Ublituximab, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Trastuzumab
Other interactions of Ublituximab
Frequently asked questions
Can I take Trastuzumab with Ublituximab?
MediHelp rates the interaction as minor. Trastuzumab and Ublituximab have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Ublituximab depletes B cells and can cause infections, while trastuzumab is generally not substantially immunosuppressive. Additive infection risk is therefore largely theoretical, though patients receiving cancer therapy may be more vulnerable.
How serious is the interaction between Trastuzumab and Ublituximab?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for signs of infection and screen for hepatitis B before ublituximab. Delay live vaccines and review neutropenia risk if combined with chemotherapy.
What other medicines interact with Trastuzumab?
MediHelp also lists interactions of Trastuzumab with, for example, Daunorubicin, Doxorubicin liposomal, Doxorubicin. The full list is on the Trastuzumab page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
